Article (Scientific journals)
Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study.
Danese, Silvio; Hart, Ailsa; Dignass, Axel et al.
2016In BMJ Open Gastroenterology, 3 (1), p. 000092
Peer Reviewed verified by ORBi
 

Files


Full Text
Effectiveness of budesonide MMW (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis...-BMJGAST-PostPE.pdf
Publisher postprint (389.99 kB)
Download

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/


All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
IBD CLINICAL; INFLAMMATORY BOWEL DISEASE; ULCERATIVE COLITIS
Abstract :
[en] INTRODUCTION: A study has been developed to assess the use and effectiveness of budesonide MMX for mild-to-moderate active ulcerative colitis (UC) in routine clinical practice. METHODS AND ANALYSIS: A prospective, multicentre, observational, cohort study of 300 patients prescribed budesonide MMX for the treatment of mild-to-moderate active UC will be conducted in Europe, Israel and Canada. Patients will be treated with budesonide MMX9 mg daily for induction of remission for </=8 weeks. Data on effectiveness, including patient-reported outcomes, tolerability and use will be recorded at the end of treatment and at >/=2 weeks after. The primary outcome (improvement >/=3 point in the clinical subscores of the UC Disease Activity Index score at the end of treatment) will be compared in: patients who receive budesonide MMX added to mesalazine >2 weeks after increased/optimised mesalazine dose for the treatment of flare (late add-on); patients who receive budesonide MMX added to mesalazine </=2 weeks since mesalazine increased/optimised for the treatment of flare, or without mesalazine dose modification (early add-on); and patients who receive budesonide MMX as monotherapy for the treatment of flare (mono). Propensity scoring will be used to minimise bias and confounding inherent in observational studies. ETHICS AND DISSEMINATION: First ethical approval: Ethikkommission der Arztekammer Hamburg (12/22/2015). The results will be published in full. DISCUSSION: Completion of primary data collection is expected in December 2017. Our results will provide further evidence on the effectiveness of budesonide MMX to support clinicians in their daily practice and inform therapeutic guidelines. TRIAL REGISTRATION NUMBER: NCT02586259.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Danese, Silvio
Hart, Ailsa
Dignass, Axel
Louis, Edouard  ;  Université de Liège > Département des sciences cliniques > Hépato-gastroentérologie
D'Haens, Geert
Dotan, Iris
Rogler, Gerhard
D'Agay, Laurence
Iannacone, Claudio
Peyrin-Biroulet, Laurent
Language :
English
Title :
Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study.
Publication date :
2016
Journal title :
BMJ Open Gastroenterology
eISSN :
2054-4774
Publisher :
BMJ Publishing Group, Londres, United Kingdom
Volume :
3
Issue :
1
Pages :
e000092
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 26 January 2017

Statistics


Number of views
57 (3 by ULiège)
Number of downloads
78 (2 by ULiège)

Scopus citations®
 
8
Scopus citations®
without self-citations
8
OpenCitations
 
6

Bibliography


Similar publications



Contact ORBi